The U.S. Cancer Moonshot is announced

Historical milestone — this page describes an event dated 2016. It is not current breaking news.

A metaphor, and a budget

President Barack Obama called for a national cancer Moonshot in his 2016 State of the Union address and asked Vice President Joe Biden to lead it. On 1 February 2016 the White House published the details.

The announcement was a $1 billion initiative. It began with $195 million in new cancer work at the National Institutes of Health in fiscal year 2016. The fiscal year 2017 budget was to propose $755 million more, split between NIH and the FDA. Defense and Veterans Affairs were raising their cancer research spending too.

A Cancer Moonshot Task Force, chaired by the Vice President, had been set up the week before.

NCI states the goal plainly: a decade's worth of progress in cancer prevention, diagnosis and treatment in five years. The 21st Century Cures Act funded the work. The initiative was reestablished in 2022.

The scientific claim underneath it

The White House document made an argument about biology, not just money.

Cancer, it said, is hundreds of diseases, each with its own drivers and weak points. That is why a single cure was never the target.

It named the openings it judged ready. Immunotherapy turns the immune system on cancer cells. It had already worked in melanoma, leukemia and lymphoma, and looked worth extending. Our page on immunotherapy explains how it works.

Drug combinations were the second bet. Attack several pathways at once, and the tumor has a harder time growing resistant.

The stated method was duller than either: better data access, and joint work between researchers, doctors, funders, patients and companies.

What the money was pointed at

The 2016 fact sheet listed the research areas.

• Cancer vaccines. Some guard against viruses that cause cancer. Others target the gene changes in one person's tumor.
• Early detection. New lab methods could make blood tests sensitive enough to screen with.
• Immunotherapy and drug combinations, pushed toward solid tumors. Trials were to run through community clinics, with a stated push to include groups often left out.
• Gene analysis of tumors and the cells around them.
• Data sharing between public and private institutions.
• A virtual FDA Oncology Center of Excellence, pooling reviewers for drugs, biologics and devices.
• Drug screening for childhood cancers.

What actually came of it

NCI reports the Moonshot supported 250 research projects and more than 70 programs and consortia. Its own list of accomplishments is specific.

It built the NCI Cancer Research Data Commons, a national store of shared cancer data. It set up one immune-therapy network for adults and another for children. It funded work on how cancers grow resistant to drugs that once worked.

It built the Human Tumor Atlas Network. That project tracks the gene damage inside one tumor as it grows from a precancerous patch into advanced cancer.

It stepped up work on fusion oncoproteins, a major driver of childhood cancer, and on drugs that block them.

And it did one dull, useful thing. It sped up guidelines for tracking symptoms that patients report, to cut the worst side effects of treatment. Nobody wins a prize for that. Patients notice it.

The screening question it left open

The Moonshot created the Cancer Screening Research Network and is supporting the Vanguard Study.

That study looks at multi-cancer detection tests. These are blood tests that hunt for signals from many cancers at once.

The questions it asks are careful ones. Do the benefits outweigh the harms? And does finding cancer early this way actually cut deaths?

The second is the hard one. A test can find more cancer without saving more lives, if what it finds would never have caused harm. Our page on multi-cancer early detection blood tests covers where the evidence stands.

When to get checked

Nothing from the Moonshot changes what a person should do this year. The screening that has evidence behind it already has thresholds.

The US Preventive Services Task Force gives colorectal cancer screening a grade A for adults aged 50 to 75 and a grade B for adults aged 45 to 49. It gives annual low-dose CT lung screening a grade B for adults aged 50 to 80 with a 20 pack-year smoking history who smoke now or quit within the last 15 years.

Symptoms sit outside any schedule. Book an appointment for a lump that will not go away, weight loss with no cause, or bleeding with no cause. Also for a cough or hoarseness past three weeks, a mole that changes, or pain that keeps coming back. Most turn out to be something else. Our page on cancer screening overview sets out which programs exist and who they are for.

The scale being addressed

The White House cited more than 1.6 million new US cancer cases and an estimated 600,000 cancer deaths for 2016.

The American Cancer Society now projects 2,114,850 new US cancer cases and 626,140 deaths for 2026, a forecast SEER republishes. Five-year relative survival across all sites for 2016 to 2022 cases is 70.5 percent. In the mid-1970s that figure was about 50 percent. Median age at diagnosis is 67, and roughly 39.2 percent of Americans will be diagnosed with cancer at some point.

An estimated 18,640,213 people were living with cancer in the United States in 2023.

These are national totals covering every cancer type. They cannot describe an individual. Rising case counts partly reflect a larger, older population rather than rising risk.

What this story cannot tell you

This was a funding and coordination effort. No treatment came from the announcement itself, and no result can be attributed to a press release.

The five-year compression goal was aspirational. Reestablishing the initiative in 2022 with new goals is itself a comment on how much work remained.

Programs, networks and shared data are inputs. Whether they change how long people live shows up years later. Pulling their effect apart from everything else happening in oncology is genuinely hard.

And none of it decides one person's care. The screening programs that existed in 2016 are still the ones with evidence behind them.

Sources

• White House archive, FACT SHEET: Investing in the National Cancer Moonshot, 1 February 2016 — https://obamawhitehouse.archives.gov/the-press-office/2016/02/01/fact-sheet-investing-national-cancer-moonshot
• NCI, Cancer Moonshot — https://www.cancer.gov/research/progress/moonshot-cancer-initiative
• US Preventive Services Task Force, Colorectal Cancer: Screening — https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
• US Preventive Services Task Force, Lung Cancer: Screening — https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
• SEER Cancer Stat Facts, Cancer of Any Site — https://seer.cancer.gov/statfacts/html/all.html

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us